Oruka Therapeutics, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Oruka Therapeutics, Inc. (ORKA) reported Restructuring and Related Cost, Number of Positions Eliminated of 12 Employee for the 12-month period ending 2022-12-31, per its 10-K filed 2024-02-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2024-02-01
- Oruka Therapeutics, Inc. restructuring and related cost, number of positions eliminated for fiscal 2022 was 12.00 Employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|---|
| 2022-12-31 | 12.00 Employee 10-K · filed 2024-02-01 | |
| 2022-07-31 | 12.00 Employee 10-Q · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |